免疫腫瘍学市場：タイプ、適応症、エンドユーザー別-2025-2030年の世界予測

免疫腫瘍学市場は、2023年に53億6,000万米ドルと評価され、2024年には58億9,000万米ドルに達すると予測され、CAGR 9.99％で成長し、2030年には104億5,000万米ドルに達すると予測されています。

免疫腫瘍学は、がんと闘うために身体の免疫システムを活用することに焦点を当てた、急速に進歩している分野です。免疫チェックポイント阻害剤、がんワクチン、細胞療法など、がん患者の生存率やQOLの向上を目的とした様々な治療法が含まれます。免疫腫瘍学の必要性は、しばしば重篤な副作用を引き起こし、病気をコントロールする効果に限界がある化学療法などの従来のがん治療の限界に由来します。この分野は、がん細胞に対して特異的に免疫応答を活性化する標的介入を提供することを目的としており、がん治療の有望な代替手段を提供するものです。免疫腫瘍学の応用範囲は、メラノーマ、肺がん、大腸がんなどさまざまながん種の治療から、効果を高める併用療法まで多岐にわたる。最終用途の範囲は主に病院、がん研究センター、専門クリニックを対象としています。

免疫腫瘍学市場は、がん罹患率の増加、バイオテクノロジーの進歩、腫瘍免疫学の理解向上といった要因の影響を受けています。個別化医療に対する需要の高まりと研究開発への継続的な注力は、市場成長をさらに後押しします。しかし、高額な治療費、複雑な規制経路、特定のがんにおける限定的な患者反応といった課題が大きな障害となっています。こうした課題にもかかわらず、この分野には、特に患者層別化のための新規バイオマーカーの開発、併用療法の有効性の向上、細胞療法の適用拡大など、有利なビジネスチャンスがあります。二重特異性抗体の探索、T細胞療法の有効性の向上、創薬と薬剤開発にAIを活用するなどの革新的な技術があふれています。

こうした機会を捉えるため、利害関係者は共同研究、バイオテクノロジー企業との戦略的提携、新興技術への投資に注力すべきです。さらに、コストに関連する課題への対処と、患者の治療薬へのアクセスの改善も、引き続き極めて重要です。市場力学はダイナミックで競争が激しく、急速な技術進歩や臨床試験の重視を特徴としています。この変革的な分野で持続的な成長と成功を収めるためには、継続的なイノベーションと、進化する科学的洞察や市場の需要への戦略的適応が不可欠です。

市場力学：急速に進化する免疫腫瘍学市場の主要な市場洞察の解明

免疫腫瘍学市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のがん患者数の増加
  • がん管理に対する政府の積極的な取り組み
  • 免疫療法と標的療法への嗜好の高まり
• 市場抑制要因
  • 免疫腫瘍学に関連する高額な医療費
• 市場機会
  • 研究開発活動のための資金調達の急増
  • 個別化医療と精密腫瘍学の拡大
• 市場の課題
  • 免疫腫瘍学の健康への悪影響に関する懸念

ポーターの5つの力：免疫腫瘍学市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、免疫腫瘍学市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：免疫腫瘍学市場における外部からの影響の把握

外部マクロ環境要因は、免疫腫瘍学市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析免疫腫瘍学市場における競合情勢の把握

免疫腫瘍学市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス免疫腫瘍学市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、免疫腫瘍学市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨免疫腫瘍学市場における成功への道筋を描く

免疫腫瘍学市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でがん患者の負担が増加
    • がん管理に対する政府の好ましい取り組み
    • 免疫療法と標的療法への関心が高まる
  • 抑制要因
    • 免疫腫瘍学に関連する高額医療費
  • 機会
    • 研究開発活動への資金の急増
    • 個別化医療と精密腫瘍学の拡大
  • 課題
    • 免疫腫瘍学の健康への悪影響に関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 免疫腫瘍学市場：タイプ別

• がんワクチン
• チェックポイント阻害剤
• サイトカイン
• 免疫細胞療法（CAR-T）
• モノクローナル抗体

第7章 免疫腫瘍学市場適応症別

• 乳がん
• 大腸がん
• 肺がん
• 悪性黒色腫

第8章 免疫腫瘍学市場：エンドユーザー別

• 学術・調査機関
• 病院・クリニック

第9章 南北アメリカの免疫腫瘍学市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の免疫腫瘍学市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの免疫腫瘍学市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Adaptimmune Therapeutics PLC
• Adicet Bio, Inc.
• Agilent Technologies, Inc.
• Allogene Therapeutics
• Amgen Inc.
• Arcus Biosciences, Inc.
• Asher Biotherapeutics, Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Atara Biotherapeutics, Inc.
• Autolus Therapeutics PLC
• Avantor, Inc.
• BeiGene, Inc.
• Bio-Rad Laboratories, Inc.
• BioNTech SE
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb
• Cellectis SA
• F. Hoffmann-La Roche AG
• Fate Therapeutics Inc.
• Merck KGaA
• Sanofi S.A.
• Thermo Fisher Scientific Inc.
• Triumvira Immunologics Inc.

LIST OF FIGURES

• FIGURE 1. IMMUNO-ONCOLOGY MARKET RESEARCH PROCESS
• FIGURE 2. IMMUNO-ONCOLOGY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. IMMUNO-ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. IMMUNO-ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. IMMUNO-ONCOLOGY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. IMMUNO-ONCOLOGY MARKET DYNAMICS
• TABLE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY IMMUNE CELL THERAPY (CAR-T), BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 31. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 48. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 51. INDIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 103. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 115. POLAND IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. POLAND IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 118. QATAR IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. QATAR IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 148. IMMUNO-ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. IMMUNO-ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2023

The Immuno-Oncology Market was valued at USD 5.36 billion in 2023, expected to reach USD 5.89 billion in 2024, and is projected to grow at a CAGR of 9.99%, to USD 10.45 billion by 2030.

Immuno-oncology is a rapidly advancing field focusing on harnessing the body's immune system to fight cancer. Its scope involves various therapies, such as immune checkpoint inhibitors, cancer vaccines, and cell therapies, which aim to improve survival rates and quality of life for cancer patients. The necessity of immuno-oncology stems from the limitations of traditional cancer therapies, such as chemotherapy, which often result in severe side effects and limited efficacy in controlling the disease. This field aims to provide targeted interventions that activate an immune response specifically against cancer cells, offering a promising alternative for cancer treatment. Applications of immuno-oncology span from treating various cancer types, including melanoma, lung, and colorectal cancers, to combination therapies that enhance effectiveness. The end-use scope primarily targets hospitals, cancer research centers, and specialized clinics.

The market for immuno-oncology is influenced by factors such as increased cancer prevalence, advancements in biotechnology, and improved understanding of tumor immunology. The rising demand for personalized medicine and the ongoing focus on R&D further propel market growth. However, challenges such as high treatment costs, complex regulatory pathways, and limited patient response in certain cancers pose significant hurdles. Despite these challenges, the field presents lucrative opportunities, particularly in developing novel biomarkers for patient stratification, enhancing the efficacy of combinatory therapies, and expanding the application of cell therapies. Innovations abound in exploring bispecific antibodies, enhancing T-cell therapy effectiveness, and leveraging AI for drug discovery and development.

To seize these opportunities, stakeholders should focus on collaborative research efforts, strategic partnerships with biotechnology firms, and investments in emerging technologies. Additionally, addressing cost-related challenges and improving patient access to therapies remain crucial. The nature of the immuno-oncology market is dynamic and highly competitive, characterized by rapid technological advancements and a strong emphasis on clinical trials. Continued innovation and strategic adaptation to evolving scientific insights and market demands are essential for sustained growth and success in this transformative field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immuno-Oncology Market

The Immuno-Oncology Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing burden of cancer cases across the globe
  • Favorable government initiatives for cancer management
  • Growing preference for immunotherapy and targeted therapies
• Market Restraints
  • Associated high medical expenses of immuno-oncology
• Market Opportunities
  • Surge in fundings for research and development activities
  • Expansion of personalized medicine and precision oncology
• Market Challenges
  • Concern regarding adverse health impacts of immuno-oncology

Porter's Five Forces: A Strategic Tool for Navigating the Immuno-Oncology Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immuno-Oncology Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immuno-Oncology Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immuno-Oncology Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immuno-Oncology Market

A detailed market share analysis in the Immuno-Oncology Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immuno-Oncology Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immuno-Oncology Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immuno-Oncology Market

A strategic analysis of the Immuno-Oncology Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immuno-Oncology Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Adicet Bio, Inc., Agilent Technologies, Inc., Allogene Therapeutics, Amgen Inc., Arcus Biosciences, Inc., Asher Biotherapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Atara Biotherapeutics, Inc., Autolus Therapeutics PLC, Avantor, Inc., BeiGene, Inc., Bio-Rad Laboratories, Inc., BioNTech SE, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Cellectis SA, F. Hoffmann-La Roche AG, Fate Therapeutics Inc., Merck KGaA, Sanofi S.A., Thermo Fisher Scientific Inc., and Triumvira Immunologics Inc..

Market Segmentation & Coverage

This research report categorizes the Immuno-Oncology Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Cancer Vaccines, Checkpoint Inhibitors, Cytokines, Immune Cell Therapy (CAR-T), and Monoclonal Antibodies.
• Based on Indication, market is studied across Breast Cancer, Colorectal Cancer, Lung Cancer, and Melanoma.
• Based on End-Users, market is studied across Academic & Research Institutions and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing burden of cancer cases across the globe
    • 5.1.1.2. Favorable government initiatives for cancer management
    • 5.1.1.3. Growing preference for immunotherapy and targeted therapies
  • 5.1.2. Restraints
    • 5.1.2.1. Associated high medical expenses of immuno-oncology
  • 5.1.3. Opportunities
    • 5.1.3.1. Surge in fundings for research and development activities
    • 5.1.3.2. Expansion of personalized medicine and precision oncology
  • 5.1.4. Challenges
    • 5.1.4.1. Concern regarding adverse health impacts of immuno-oncology
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Immuno-Oncology Market, by Type

• 6.1. Introduction
• 6.2. Cancer Vaccines
• 6.3. Checkpoint Inhibitors
• 6.4. Cytokines
• 6.5. Immune Cell Therapy (CAR-T)
• 6.6. Monoclonal Antibodies

7. Immuno-Oncology Market, by Indication

• 7.1. Introduction
• 7.2. Breast Cancer
• 7.3. Colorectal Cancer
• 7.4. Lung Cancer
• 7.5. Melanoma

8. Immuno-Oncology Market, by End-Users

• 8.1. Introduction
• 8.2. Academic & Research Institutions
• 8.3. Hospitals & Clinics

9. Americas Immuno-Oncology Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Immuno-Oncology Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Immuno-Oncology Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Adaptimmune Therapeutics PLC
• 3. Adicet Bio, Inc.
• 4. Agilent Technologies, Inc.
• 5. Allogene Therapeutics
• 6. Amgen Inc.
• 7. Arcus Biosciences, Inc.
• 8. Asher Biotherapeutics, Inc.
• 9. Astellas Pharma Inc.
• 10. AstraZeneca PLC
• 11. Atara Biotherapeutics, Inc.
• 12. Autolus Therapeutics PLC
• 13. Avantor, Inc.
• 14. BeiGene, Inc.
• 15. Bio-Rad Laboratories, Inc.
• 16. BioNTech SE
• 17. Boehringer Ingelheim International GmbH
• 18. Bristol Myers Squibb
• 19. Cellectis SA
• 20. F. Hoffmann-La Roche AG
• 21. Fate Therapeutics Inc.
• 22. Merck KGaA
• 23. Sanofi S.A.
• 24. Thermo Fisher Scientific Inc.
• 25. Triumvira Immunologics Inc.